

Ref: FOI/GS/ID 8276

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

30 June 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to renal cell carcinoma and melanoma.

You asked:

Results below for the period 1/3/2023-31/5/2023.

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

- a. Avelumab + Axitinib*
- b. Axitinib*
- c. Cabozantinib*
- d. Everolimus*
- e. Ipilimumab monotherapy*
- f. Lenvatinib + Everolimus*
- g. Nivolumab monotherapy*
- h. Nivolumab + Cabozantinib*
- i. Nivolumab + Ipilimumab*
- j. Pazopanib*
- k. Pembrolizumab + Axitinib*
- l. Pembrolizumab + Lenvatinib*
- m. Pembrolizumab monotherapy*
- n. Radiotherapy only*
- o. Sunitinib*
- p. Temsirolimus*
- q. Tivozanib*
- r. Other active systemic anti-cancer therapy*
- s. Palliative care only*

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- a. Cobimetinib*

- b. Dabrafenib
- c. Dabrafenib AND Trametinib
- d. Dacarbazine
- e. Encorafenib AND Binimetinib
- f. Ipilimumab
- g. Ipilimumab AND Nivolumab
- h. Nivolumab
- i. Pembrolizumab
- j. Trametinib
- k. Vemurafenib
- l. Vemurafenib AND Cobimetinib
- m. Other active systemic anti-cancer therapy
- n. Palliative care only

Q3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- a. Ipilimumab
- b. Ipilimumab AND Nivolumab
- c. Nivolumab
- d. Pembrolizumab
- e. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- f. Other active systemic anti-cancer therapy
- g. Palliative care only

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Trust response:

Results below for the period 1/3/2023-31/5/2023.

Q1.

- a. 5
- b. 8
- c. 7
- d. 2
- e. 0
- f. 0
- g. 5
- h. 0
- i. 0
- j. 7
- k. 0
- l. 5
- m. 2
- n. 11
- o. 3
- p. 0
- q. 0
- r. 0
- s. 2

Q2.

a. 0

b. 0

c. 29

d. 0

e. 7

f. 2

g. 14

h. 8

i. 52

j. 0

k. 1

l. 0

m. 1

n. 0

Q3.

a. 1

b. 14

c. 3

d. 20

e. 16

f. 0

g. 0

Q4. 0